Gemtuzumab Ozogamicin in Children With Relapsed or Refractory Acute Myeloid Leukemia: A Report of Berlin-Frankfurt-Münster Study Group

Haematologica - Italy
doi 10.3324/haematol.2018.191841
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Leukemia Research
Cancer ResearchOncologyHematology
2011English

Antibody-Based Therapy of Acute Myeloid Leukemia With Gemtuzumab Ozogamicin

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2013English

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report From the Children's Oncology Group

Clinical Cancer Research
Cancer ResearchOncology
2015English

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Hematology International
2019English

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

Advances in Therapy
MedicinePharmacology
2019English

The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia

Oncologist
Cancer ResearchMedicineOncology
2019English

Salvage Treatment for Refractory or Relapsed Acute Myeloid Leukemia: A 10-Year Single-Center Experience

Clinics
Medicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy